Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Express Scripts
Merck
McKesson
Boehringer Ingelheim

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LYSTEDA

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Lysteda

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00113568 Safety Study of XP12B in Women With Menorrhagia Completed Ferring Pharmaceuticals Phase 3 2005-06-01 The purpose of this study is to evaluate the safety of XP12B in women with heavy menstrual bleeding associated with menorrhagia.
NCT00386308 Efficacy and Safety Study of XP12B in Women With Menorrhagia Completed Ferring Pharmaceuticals Phase 3 2006-10-01 The purpose of this study is to determine whether XP12B is effective and safe in the treatment of women with heavy menstrual bleeding associated with menorrhagia.
NCT00401193 Efficacy and Safety of XP12B in Women With Menorrhagia Completed Ferring Pharmaceuticals Phase 3 2006-11-01 The purpose of this study is to determine whether XP12B is effective and safe in the treatment of women with heavy menstrual bleeding associated with menorrhagia.
NCT01190150 Lysteda Pediatric Research Equity Act (PREA) Pharmacokinetic Study in Adolescent Females With Heavy Menstrual Bleeding Completed Ferring Pharmaceuticals Phase 4 2010-08-01 This is a Phase 4, randomized, 2-way crossover, pharmacokinetic study of Lysteda (tranexamic acid) tablets administered as single doses of 0.65 g and 1.3 g in fasting adolescent female subjects ages 12-16 years with heavy menstrual bleeding.
NCT01659008 Estradiol vs Lysteda in Treatment of Heavy Menstrual Bleeding Recruiting American College of Obstetricians and Gynecologists N/A 2012-06-01 Treatment with Estradiol is non-inferior to treatment with Tranexamic acid in reducing the amount and duration of menstrual blood loss in women with cyclic heavy menstrual bleeding
NCT01659008 Estradiol vs Lysteda in Treatment of Heavy Menstrual Bleeding Recruiting Kay I Waud MD PhD N/A 2012-06-01 Treatment with Estradiol is non-inferior to treatment with Tranexamic acid in reducing the amount and duration of menstrual blood loss in women with cyclic heavy menstrual bleeding
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lysteda

Condition Name

Condition Name for Lysteda
Intervention Trials
Heavy Menstrual Bleeding 5
Menorrhagia 5
Blood Loss, Surgical 2
Hematologic Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Lysteda
Intervention Trials
Hemorrhage 10
Menorrhagia 8
Osteoarthritis 2
Blood Loss, Surgical 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Lysteda

Trials by Country

Trials by Country for Lysteda
Location Trials
United States 95
United Kingdom 1
Australia 1
Brazil 1
Mexico 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Lysteda
Location Trials
California 4
Ohio 4
Nebraska 3
Colorado 3
Florida 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Lysteda

Clinical Trial Phase

Clinical Trial Phase for Lysteda
Clinical Trial Phase Trials
Phase 4 4
Phase 3 6
Phase 2 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Lysteda
Clinical Trial Phase Trials
Completed 5
Recruiting 4
Not yet recruiting 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Lysteda

Sponsor Name

Sponsor Name for Lysteda
Sponsor Trials
Ferring Pharmaceuticals 4
University of North Carolina 1
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Lysteda
Sponsor Trials
Other 14
Industry 4
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Dow
Colorcon
Express Scripts
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.